Regulation of human dendritic cells by a novel specific nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin

Kazunobu Shinoda, Ken Nakagawa, Takeo Kosaka, Nobuyuki Tanaka, Takahiro Maeda, Hidaka Kono, Ryuichi Mizuno, Eiji Kikuchi, Akira Miyajima, Kazuo Umezawa, Mototsugu Oya

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Regulation of antigen-presenting cells (APC) is crucial in controlling allograft rejection. Dendritic cells (DC) are the most potent APC and must mature to present antigens to T-cell receptors. During DC maturation, nuclear factor-κB (NF-κB) is a key transcriptional factor. We synthesized dehydroxymethylepoxyquinomicin (DHMEQ), which specifically inhibits the final step of nuclear translocation of activated NF-κB proteins and examined its immunoregulatory effects on human monocyte-derived DC (Mo-DC). Regulatory Mo-DC were generated by pretreatment with DHMEQ before LPS stimulation, which were termed dl-DC. DHMEQ pretreatment (5 μg/ml) completely inhibited nuclear translocation of activated NF-κB. DHMEQ significantly inhibited DC production of κproinflammatory cytokines (IL-6, TNF-α, and IL-12 p70) in a dose-dependent manner. IL-12 was most potently inhibited. However, IL-10 production by dl-DC was only moderately affected by DHMEQ. Although CD40 and the expression of HLA-DR (HLA-DR) expression on dl-DC was downregulated, CD80 and CD86 expression was moderately upregulated. Induction of T helper 1 cell responses was efficiently impaired by dl-DC. This confirmed that DHMEQ-treated Mo-DC exhibited immunoregulatory effects. These findings suggest that DHMEQ has potential as an immunosuppressive drug for human immune cells.

Original languageEnglish
Pages (from-to)763-770
Number of pages8
JournalHuman Immunology
Volume71
Issue number8
DOIs
Publication statusPublished - 2010 Aug

Fingerprint

Dendritic Cells
Monocytes
HLA-DR Antigens
Antigen-Presenting Cells
Interleukin-12
Th1 Cells
dehydroxymethylepoxyquinomicin
Immunosuppressive Agents
T-Cell Antigen Receptor
Interleukin-10
Allografts
Interleukin-6
Down-Regulation
Cytokines
Pharmaceutical Preparations
Proteins

Keywords

  • Dendritic cells
  • Immunoregulation
  • NF-κB inhibitor

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Regulation of human dendritic cells by a novel specific nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin. / Shinoda, Kazunobu; Nakagawa, Ken; Kosaka, Takeo; Tanaka, Nobuyuki; Maeda, Takahiro; Kono, Hidaka; Mizuno, Ryuichi; Kikuchi, Eiji; Miyajima, Akira; Umezawa, Kazuo; Oya, Mototsugu.

In: Human Immunology, Vol. 71, No. 8, 08.2010, p. 763-770.

Research output: Contribution to journalArticle

Shinoda, Kazunobu ; Nakagawa, Ken ; Kosaka, Takeo ; Tanaka, Nobuyuki ; Maeda, Takahiro ; Kono, Hidaka ; Mizuno, Ryuichi ; Kikuchi, Eiji ; Miyajima, Akira ; Umezawa, Kazuo ; Oya, Mototsugu. / Regulation of human dendritic cells by a novel specific nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin. In: Human Immunology. 2010 ; Vol. 71, No. 8. pp. 763-770.
@article{1765f6b47d0c4506acac07016e9b3785,
title = "Regulation of human dendritic cells by a novel specific nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin",
abstract = "Regulation of antigen-presenting cells (APC) is crucial in controlling allograft rejection. Dendritic cells (DC) are the most potent APC and must mature to present antigens to T-cell receptors. During DC maturation, nuclear factor-κB (NF-κB) is a key transcriptional factor. We synthesized dehydroxymethylepoxyquinomicin (DHMEQ), which specifically inhibits the final step of nuclear translocation of activated NF-κB proteins and examined its immunoregulatory effects on human monocyte-derived DC (Mo-DC). Regulatory Mo-DC were generated by pretreatment with DHMEQ before LPS stimulation, which were termed dl-DC. DHMEQ pretreatment (5 μg/ml) completely inhibited nuclear translocation of activated NF-κB. DHMEQ significantly inhibited DC production of κproinflammatory cytokines (IL-6, TNF-α, and IL-12 p70) in a dose-dependent manner. IL-12 was most potently inhibited. However, IL-10 production by dl-DC was only moderately affected by DHMEQ. Although CD40 and the expression of HLA-DR (HLA-DR) expression on dl-DC was downregulated, CD80 and CD86 expression was moderately upregulated. Induction of T helper 1 cell responses was efficiently impaired by dl-DC. This confirmed that DHMEQ-treated Mo-DC exhibited immunoregulatory effects. These findings suggest that DHMEQ has potential as an immunosuppressive drug for human immune cells.",
keywords = "Dendritic cells, Immunoregulation, NF-κB inhibitor",
author = "Kazunobu Shinoda and Ken Nakagawa and Takeo Kosaka and Nobuyuki Tanaka and Takahiro Maeda and Hidaka Kono and Ryuichi Mizuno and Eiji Kikuchi and Akira Miyajima and Kazuo Umezawa and Mototsugu Oya",
year = "2010",
month = "8",
doi = "10.1016/j.humimm.2010.05.009",
language = "English",
volume = "71",
pages = "763--770",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Regulation of human dendritic cells by a novel specific nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin

AU - Shinoda, Kazunobu

AU - Nakagawa, Ken

AU - Kosaka, Takeo

AU - Tanaka, Nobuyuki

AU - Maeda, Takahiro

AU - Kono, Hidaka

AU - Mizuno, Ryuichi

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Umezawa, Kazuo

AU - Oya, Mototsugu

PY - 2010/8

Y1 - 2010/8

N2 - Regulation of antigen-presenting cells (APC) is crucial in controlling allograft rejection. Dendritic cells (DC) are the most potent APC and must mature to present antigens to T-cell receptors. During DC maturation, nuclear factor-κB (NF-κB) is a key transcriptional factor. We synthesized dehydroxymethylepoxyquinomicin (DHMEQ), which specifically inhibits the final step of nuclear translocation of activated NF-κB proteins and examined its immunoregulatory effects on human monocyte-derived DC (Mo-DC). Regulatory Mo-DC were generated by pretreatment with DHMEQ before LPS stimulation, which were termed dl-DC. DHMEQ pretreatment (5 μg/ml) completely inhibited nuclear translocation of activated NF-κB. DHMEQ significantly inhibited DC production of κproinflammatory cytokines (IL-6, TNF-α, and IL-12 p70) in a dose-dependent manner. IL-12 was most potently inhibited. However, IL-10 production by dl-DC was only moderately affected by DHMEQ. Although CD40 and the expression of HLA-DR (HLA-DR) expression on dl-DC was downregulated, CD80 and CD86 expression was moderately upregulated. Induction of T helper 1 cell responses was efficiently impaired by dl-DC. This confirmed that DHMEQ-treated Mo-DC exhibited immunoregulatory effects. These findings suggest that DHMEQ has potential as an immunosuppressive drug for human immune cells.

AB - Regulation of antigen-presenting cells (APC) is crucial in controlling allograft rejection. Dendritic cells (DC) are the most potent APC and must mature to present antigens to T-cell receptors. During DC maturation, nuclear factor-κB (NF-κB) is a key transcriptional factor. We synthesized dehydroxymethylepoxyquinomicin (DHMEQ), which specifically inhibits the final step of nuclear translocation of activated NF-κB proteins and examined its immunoregulatory effects on human monocyte-derived DC (Mo-DC). Regulatory Mo-DC were generated by pretreatment with DHMEQ before LPS stimulation, which were termed dl-DC. DHMEQ pretreatment (5 μg/ml) completely inhibited nuclear translocation of activated NF-κB. DHMEQ significantly inhibited DC production of κproinflammatory cytokines (IL-6, TNF-α, and IL-12 p70) in a dose-dependent manner. IL-12 was most potently inhibited. However, IL-10 production by dl-DC was only moderately affected by DHMEQ. Although CD40 and the expression of HLA-DR (HLA-DR) expression on dl-DC was downregulated, CD80 and CD86 expression was moderately upregulated. Induction of T helper 1 cell responses was efficiently impaired by dl-DC. This confirmed that DHMEQ-treated Mo-DC exhibited immunoregulatory effects. These findings suggest that DHMEQ has potential as an immunosuppressive drug for human immune cells.

KW - Dendritic cells

KW - Immunoregulation

KW - NF-κB inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77954761223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954761223&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2010.05.009

DO - 10.1016/j.humimm.2010.05.009

M3 - Article

VL - 71

SP - 763

EP - 770

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 8

ER -